Thymosin Alpha-1
Immunomodulatory peptide approved in some countries (e.g., for hepatitis B). Studied in immune modulation contexts.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
What the research shows
Approved in many countries (e.g., for chronic hepatitis B and as an adjunct in some immune-compromised states). Multiple clinical trials support immune-modulatory effects.
What's still experimental
Off-label uses (general immune support, COVID, oncology adjunct) have mixed and evolving evidence.
Anecdotal / community reports
Reports of fewer infections during cycles are common but not controlled.
Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.
FDA approval status
Source: openFDA + DailyMed (NIH/NLM)Doses studied in research
No established dose rangeWhat published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.
This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.
FDA enforcement & recalls
Live · openFDA Drug Enforcement APIMechanism & targets
ChEMBL · UniProt · Open TargetsMolecule (ChEMBL)
View on ChEMBLProtein targets (UniProt)
- Prothymosin alphaP06454gene: PTMAHomo sapiens· 111 aaReviewed
Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections
- Prothymosin alphaP01252gene: PTMABos taurus· 110 aaReviewed
Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections
- Prothymosin alphaP06302gene: PtmaRattus norvegicus· 112 aaReviewed
Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections
Live research
PubMed · ClinicalTrials.gov · Europe PMC · OpenAlexClinical trials (ClinicalTrials.gov)
- The Efficacy and Safety of Ta1 for SepsisCOMPLETEDNCT02867267 · PHASE3 · n=1106 · 2016-09-06
- Zadaxin and HIV-positive Patients With Immune Reconstitution DisorderCOMPLETEDNCT04963712 · EARLY_PHASE1 · n=20 · 2021-09-01
- Immunotherapy for Elderly Patients With Chronic Osteoporotic PainUNKNOWNNCT04524169 · PHASE4 · n=100 · 2020-11-01
- A Trial of Thymalfasin in Adult Patients With Hepatocellular CarcinomaCOMPLETEDNCT00082082 · PHASE2
- Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative ResectionUNKNOWNNCT02281266 · PHASE4 · n=360 · 2015-01
Europe PMC — 4,738 additional records
Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.
- Sprayable bioadhesive microcarriers loaded with Tβ4-Engineered ADSC exosomes for diabetic wound healingDing Y, Huang D, Zhao Z, et al. · 2026Open access
- Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic CellsWei Y, Chen J, Zhang Y, et al. · 2026
- Evidence Mapping and Quality Assessment of Randomized Controlled Trials in Dental TraumatologyTewari N, Jhunjhunwala G, Rajeswary A, et al. · 2026· cited 2×
- Human α1-Antitrypsin Inhibits Nociceptor Excitability and Relieves Inflammatory and Neuropathic PainWaters AL, Loya-López S, Rodriguez-Palma EJ, et al. · 2026
Research volume (OpenAlex topic graph)
Human clinical evidence
Semantic Scholar · AI TLDRs · influence-rankedHuman-study summaries for “thymosin alpha-1” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.
Research funding & verification
NIH RePORTER · CrossRef DOI registryNIH-funded research
U.S. National Institutes of Health- 1RC3HL103357-01$3.0MNonclinical Studies to Advance Novel Drug for Post-STEMI Cardiac RegenerationHynda Karen Kleinman · REGENERX BIOPHARMACEUTICALS, INC. · FY2010
- 5P50DK044757-20$935KFibrotic Sequelae of Childhood Renal DiseasaeAGNES B. FOGO · VANDERBILT UNIVERSITY · FY2011
- 5P50DK044757-19$935KFibrotic Sequelae of Childhood Renal DiseasaeAGNES B. FOGO · VANDERBILT UNIVERSITY · FY2010
- 5P50DK044757-18$935KFibrotic Sequelae of Childhood Renal DiseasaeAGNES B. FOGO · VANDERBILT UNIVERSITY · FY2009
Publication landscape
CrossRef · DOI registry- National Natural Science Foundation of China2,231 works
- National Institutes of Health1,015 works
- Deutsche Forschungsgemeinschaft417 works
- DOE340 works
- National Research Foundation of Korea280 works
- National Science Foundation279 works
Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.
Preprints — cutting edge
bioRxiv · medRxiv · via Europe PMCPreprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.
- PreprintOncogenes and tumor suppressor genes are enriched in stop-loss mutations generating protein extensionsBoll LM, Martorell JA, Khelghati N, et al. · 2026-03-16
- PreprintThe significance of thymosin α1 and intravenous immunoglobulin in the prevention of pulmonary adverse events in B-cell lymphoma treated with R-CHOP: A prospective studyShrestha PR, Shrestha K, Pudasaini P, et al. · 2026-04-23
- PreprintEfficacy of Thymosin Alpha 1 Combined with Sivelestat and Ambroxol in Elderly Sepsis-Associated ARDS: A Randomized TrialYun P, Han L, Xie Z, et al. · 2025-09-24
- PreprintStabilisation of HIF signalling in the mouse epicardium extends embryonic potential and neonatal heart regenerationGamen E, Price E, Pezzolla D, et al. · 2025-08-28
- PreprintVincristine treatment reverses podocyte damage in focal segmental glomerulosclerosisMason WJ, Chandler JC, Pomeranz G, et al. · 2024-11-15
- PreprintLocal inflammation at the salmon louse (Lepeophtheirus salmonis) attachment site drives copepodid rejection in Coho Salmon (Oncorhynchus kisutch)Sveen L, Fast MD, Tengs T, et al. · 2024-09-23
Known risks
Should only be used under licensed clinical supervision.
Reported side effects
Generally well tolerated in approved indications.
FDA adverse event reports (FAERS)
Updated quarterly by FDA- CN12
- IN5
- US1
Most-reported reactions
- Off Label Use8
- Fatigue3
- Abortion Spontaneous2
- Anaemia2
- Interstitial Lung Disease2
- Nausea2
- Pain2
- Peripheral Ischaemia2
- Pneumonia2
- Pregnancy2
Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs
What requires medical supervision
Should only be used under licensed clinical supervision. Drug interactions and immune-modulation effects warrant monitoring.
Questions for your clinician
- Is this approved or off-label for my situation?
- What baseline immune labs should we check?
- How will we measure benefit objectively?